Hardy Diagnostics Recalls HardyDisk AST Cefiderocol (Z-2887-2026)
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Hardy Diagnostics is recalling 43 units of HardyDisk AST Cefiderocol 30μg (FDC30) REF Z9435 due to incorrect cartridges that may cause false susceptibility results.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 19, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Devices.
What Happened
Hardy Diagnostics initiated a voluntary recall of affected HardyDisk AST Cefiderocol products after determining that incorrect cartridges were included, creating the potential for false-susceptible or false-resistant susceptibility results.
Which Products Are Affected
- Product: HardyDisk AST Cefiderocol 30μg (FDC30) REF Z9435
- Catalog Number: Z9435
- Lot Number: 543461
- Quantity: 43 units
- Distribution: U.S. Nationwide in AZ, CA, FL, ID, IN, MA, MS, NJ, NV, NY, OH, PA, and TN
- Recall Number: Z-2887-2026
- Classification: Class II
What You Should Do
Healthcare providers and laboratories should discontinue use of the affected lot and contact Hardy Diagnostics regarding the recall.
Why This Matters
The recall affects in vitro susceptibility testing for Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii complex, and Stenotrophomonas maltophilia, with potential to lead to selection of ineffective antimicrobial therapy.
Source
FDA recall Z-2887-2026, https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,079 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 19, 2026.
Frequently Asked Questions
Common questions about this FDA recall.